Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention (APACHE-2)

11 september 2014 bijgewerkt door: University Hospital, Tours

Attitudes to Different Strategies Among Women Not Attending Cervical Cancer Screening: Further Invitation by Mail or Kit for Self-collected Vaginal Sample

Scientific Context:

High-risk types of human papillomavirus (HPV) are the causative agents for cervical cancer. Cervical cancer screening strategies rely on periodic Papanicolaou (Pap) testing. It's well-known that this test has significantly contributed to the reduction of mortality and morbidity due to cervical cancer. In France, it now seems that the screening strategy could be optimized. The two main ways are to reach the 7 million underscreened women (organized screening, self-sampling for HPV DNA testing) and to improve the screening test (HPV DNA testing, computer-assisted cytology). Self-collected vaginal samples (SCVS) for HPV DNA testing could be a relevant screening option: this technique appears reliable and it could allow to reach women who are never or seldom screened. The performance of the SCVS to detect cervical HPV infection has been assessed by the first part of the whole study: APACHE-1.

The goal of this study is to compare the attitudes of women not attending organized cervical cancer screening face to different strategies: further invitation to make a cervical smear or kit for self-collected vaginal sample sent at home.

Description of the project :

Nine months after a primary invitation to make a cervical smear, a random sample of 6000 women not attending organized cervical cancer screening will be randomly assigned to one of the following arms:

  • Intervention arm 1:

Women will receive a further invitation to make a cervical smear

  • Intervention arm 2:

Women will be directly sent the kit for self-collected vaginal sample at home. The women who will send the self-sample to the laboratory for analyse will receive their results at home as well as their general practitioner if the HPV DNA test is positive (infection by a high-risk HPV).

For them who will have a HPV DNA test positive, it will be necessary to complete the screening action with a cervical smear. That's why those women will receive an invitation to make a cervical smear if they won't do it during the 9 months following the first mail.

  • Control arm: Those women will receive complete information about the study, the main results and the screening recommendations at the end of the study.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Werkelijk)

5998

Fase

  • Vroege fase 1

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

30 jaar tot 65 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

Inclusion Criteria :

  • Women from 30 to 65 years
  • Living in Indre-et-Loire (french territorial division 37)

Exclusion Criteria :

  • Women who attend organized cervical cancer screening or who answer to the invitation
  • Cervical smear made in the three last years
  • HPV linked cervical condition undergoing treatment
  • Hysterectomy (including cervix)

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Screening
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Group 1 : Further invitation by mail
Further invitation to attend for cervical cytology
A further invitation to attend for cervical cytology are going to be sent by mail to women
Experimenteel: Group 2 : Kit for Self-collected vaginal sample
Kit for Self-collected vaginal sample sent at home and then test for Human Papillomavirus (HPV)
Kit for self-collected vaginal sample are going to be directly sent at women's home
Geen tussenkomst: Group 3: Control

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Comparison of women's attitude according to the arm: participation or not to a whole screening action
Tijdsspanne: 9 months after the beginning of the study (sending of mails)

Comparison of attitudes among women not attending organized cervical cancer according to the type of intervention or the lack of intervention: participation or not to a whole screening action.

Are considered as whole screening action:

  • cervical smear
  • HPV DNA testing on self-collected vaginal sample negative (no infection by a high-risk HPV)
  • HPV DNA testing on self-collected vaginal sample positive (infection by a high-risk HPV) followed by a cervical smear
9 months after the beginning of the study (sending of mails)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Analysis in sub-groups
Tijdsspanne: 9 months after the beginning of the study (sending of mails)

Analysis in sub-groups in order to compare the efficacy of interventions according to :

  • The age
  • Health insurance system
  • Distribution map (urban area, peri-urban area, rural area)
9 months after the beginning of the study (sending of mails)
Identification of the psychological determinants and mechanisms (checks and motivational factors)
Tijdsspanne: 9 months after the beginning of the study (sending of mails)

Identify the psychological determinants and mechanisms (checks and motivational factors) that can affect enrollment to the screening procedure for self-collection vaginal sample or cervical smear.

Nine months after the beginning of the study, a questionnaire will be send to the 6000 women.

9 months after the beginning of the study (sending of mails)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Ken HAGUENOER, François Rabelais University, Public Health Laboratory, Tours, France

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start

1 februari 2012

Primaire voltooiing (Werkelijk)

1 december 2012

Studie voltooiing (Werkelijk)

1 december 2012

Studieregistratiedata

Eerst ingediend

12 maart 2012

Eerst ingediend dat voldeed aan de QC-criteria

27 april 2012

Eerst geplaatst (Schatting)

30 april 2012

Updates van studierecords

Laatste update geplaatst (Schatting)

12 september 2014

Laatste update ingediend die voldeed aan QC-criteria

11 september 2014

Laatst geverifieerd

1 juli 2014

Meer informatie

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Klinische onderzoeken op Baarmoederhalskanker

3
Abonneren